Finasteride is a synthetic compound classified as a 5-alpha reductase inhibitor. It is not an endogenous hormone but is chemically synthesized for therapeutic use. Finasteride is primarily used in the management of androgen-dependent conditions such as male androgenetic alopecia (AGA) and benign prostatic hyperplasia (BPH). It is available in oral formulations, commonly known under brand names like Propecia and Proscar. Researchers have focused on its ability to inhibit the conversion of testosterone to dihydrotestosterone (DHT), a potent androgen involved in hair loss and prostate enlargement. Finasteride's primary physiological role is to reduce DHT levels, which has been shown to improve hair count in AGA and reduce prostate size in BPH. Research areas include its efficacy in hair regrowth, impact on prostate health, and associated side effects. The mechanism of action involves the selective inhibition of the 5-alpha reductase type II enzyme, which is responsible for converting testosterone into DHT. This inhibition leads to a decrease in DHT levels both systemically and locally in tissues such as the scalp and prostate. Pharmacokinetically, finasteride has an oral bioavailability and a plasma half-life of approximately 4.5 hours. It is metabolized in the liver and excreted through urine and feces. Clinically, finasteride is approved by the FDA for the treatment of male AGA and BPH. It is generally well-tolerated, though researchers have observed side effects including sexual dysfunction and potential neuropsychiatric effects such as depression. Regulatory bodies have included warnings about these side effects in product labeling.